InflaRx GmbH was founded in December 2007 in Jena, Germany, an internationally recognized acute care clinical trial hub. InflaRx developed close collaborative ties with the Jena University Medical Center, where CEO, Niels Riedemann held the position as Vice Director of Intensive Care Therapy. InflaRx was therefore able to build an in-house team with vast expertise in the acute care and inflammatory disease field.
Simultaneously, CSO, Renfeng Guo expanded the company’s collaborations with the Beijing Institute of Sciences and other renowned Chinese immunologists, allowing InflaRx to conduct top-tier immunological research abroad. These collaborations led to ground-breaking work on the role of C5a in different types of lung injury in non-human primates, and other discoveries.
2008 A Breakthrough Discovery
In 2008, InflaRx made a breakthrough discovery allowing the generation of monoclonal anti-C5a antibodies which are both highly selective (not blocking the terminal membrane attack complex) and have an extremely potent immunologic blocking activity. InflaRx's discoveries were the subject of patent applications globally; since, numerous patents have been issued in various countries.
2011 First Clinical Trial Phase I
In 2011, InflaRx started a Phase I clinical trial with an anti-C5a antibody, demonstrating that IFX-1 was safe and well tolerated.
2014 Successful Generation of IFX-2
In 2014, InflaRx successfully discovered IFX-2, a follow-on molecule of IFX-1, which has planned development for additional chronic inflammatory diseases.
2015 Phase II Trial Completed
In 2015, InflaRx completed a Phase IIa trial with IFX-1 in patients suffering from life-threatening infections and early organ dysfunction. This trial validated InflaRx’s IFX-1 technology, demonstrating that C5a can be effectively controlled and blocked by IFX-1 in this setting.
2017 Phase IIa Hidradenitis Suppurativa
In 2017, InflaRx completed a first clinical Phase IIa open-label single-center study in Hidradenitis Suppurativa (HS) patients, demonstrating a clinical response rate of 83% using the Hidradenitis Clinical Response Score (HISCR) at the end of the trial observation period in 12 patients with Hurley Stage III.
2017 InflaRx US Nasdaq IPO after Crossover Financing Round
In November 2017, InflaRx completed a successful US IPO with total gross proceeds of USD 106 million on the US Nasdaq global select market after closing a crossover financing round with a total proceeds of USD 55 million.
2018 Follow-on Transaction
In April 2018, InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market.
2019 Results from the Phase IIb SHINE trial in Hidradenitis Suppurativa (HS)
InflaRx completed the Phase IIb SHINE Study in HS. The study did not achieve its primary endpoint (dose dependent effect on the HiSCR at week 16) but the results suggest a robust anti-inflammatory activity in the high dose IFX-1 treatment group across numerous efficacy measures. Additionally, results from open label extension part of trial showed that responders maintain response to a large extent over long term treatment and roughly 42% of non-responders become responders.